
FDA approves RAS-targeted drug for metastatic pancreatic cancer
The US Food and Drug Administration (FDA) has approved Revolution Medicines’ Rasonque (daraxonrasib) once-daily oral tablets, for the treatment of adults with metastatic pancreatic adenocarcinoma (PDAC). It is approved in patients who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The… Read More















